2022
Te Whatu Ora - Southern Commercial Agreement Completed
Pacific Edge can now confirm a signed executed agreement has been received from Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. [read more]
Enhanced Cxbladder Tests Deliver Improved Diagnostic Performance
Pacific Edge today announces the acceptance for publication of new clinical evidence that shows significant improvements in the performance of its genomic diagnostic Cxbladder tests. These performance improvements were achieved by the addition of DNA biomarkers to Cxbladder Triage (CxbT) and Cxbladder Detect (CxbD). [read more]
Medical Release: Lotan et al 2022
View and download the Lotan et al 2022 Medical Release [read more]
Pacific Edge Investment for Growth Delivers Early Results
Pacific Edge today announces strong growth in revenue for the half year to the end of September 2022 as new growth investments begin to accelerate the adoption of Cxbladder, the company’s suite of advanced genomic bladder cancer diagnostic tests. [read more]
Interim Financial Results to be Announced 24 November 2022
Pacific Edge advises that its half-year results for the six months ending 30 September 2022 will be released on Thursday 24 November 2022. [read more]
Investor Update – Q2 FY23 Test Volumes Rise 36% on Q2 FY22
Pacific Edge has today released its September Quarter Investor Update showing early signs that its investment in US sales & marketing initiatives are driving Cxbladder adoption. [read more]
Pacific Edge Comments on Proposed Novitas LCD
Pacific Edge today provides further information for shareholders on proposed changes to the Medicare Local Coverage Determination (LCD) that governs the reimbursement of Cxbladder in the US. [read more]
Results from the Pacific Edge Annual Shareholder's Meeting
Results from Pacific Edge's annual shareholder meeting, held in Dunedin and online yesterday. Shareholders were asked to vote on 4 resolutions. [read more]
Pacific Edge Appoints Chief Operating Officer
Pacific Edge is pleased to announce the appointment of Darrell Morgan as Chief Operating Officer. Darrell has extensive experience in senior leadership and executive roles in large, mid-sized and virtual pharmaceutical companies in the UK, Europe and New Zealand. [read more]
2022 Annual Shareholders Meeting Presentation
Today's presentation from our Annual Shareholders Meeting. [read more]
Southern District Health Region Adopts Pacific Edge’s Cxbladder Tests
Pacific Edge today announces it has substantially completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its non-invasive Cxbladder genomic biomarker tests. [read more]
Investor Update – Q1 FY23 Test Volumes Rise 32% YOY
Pacific Edge today announces continuing strong growth in volumes through its laboratories of its market-leading genomic biomarker Cxbladder tests. [read more]
STRATA Study to Validate Cxbladder Utility Reaches 50% Enrolment
Pacific Edge today announces it has reached more than 50% enrolment in its study to demonstrate the clinical utility of its advanced genomic biomarker Cxbladder tests in safely stratifying low-risk patients presenting with blood in urine (hematuria). [read more]
Pacific Edge Appoints Vice President of Market Access
Pacific Edge today announces the appointment of David Sosa into the new role of Vice President of Market Access and Reimbursement for Pacific Edge Diagnostics USA (PEDUSA). [read more]
Pacific Edge Annual Report
Pacific Edge is pleased to present its Annual Report for the year ended 31 March 2022. [read more]
Pacific Edge Announces US Leadership Succession Plan
Pacific Edge today announces a leadership succession at its US subsidiary, Pacific Edge Diagnostics USA (PEDUSA). [read more]
Pacific Edge Appoints Vice President of Medical Affairs
Pacific Edge is today pleased to announce the appointment of Dr Tamer Aboushwareb as Vice President of Medical Affairs, PEDUSA. [read more]
Kaiser Permanente Agrees to Cxbladder EMR Integration
Pacific Edge today announces Kaiser Permanente, the largest integrated health provider in the US, has given the greenlight to incorporate Cxbladder tests within its Electronic Medical Records (EMR) system. [read more]
Pacific Edge Sees Growth Initiatives Gaining Traction
Pacific Edge today announces financial and operational results for the year to 31 March 2022 showing strong growth in the adoption of its advanced genomic biomarker Cxbladder tests and early results suggesting initial traction can be translated into faster growth. [read more]
Pacific Edge Sees Strong Interest in Cxbladder at AUA Meeting
Pacific Edge is pleased to report strong interest in its advanced genomic biomarker Cxbladder tests from the recently-concluded American Urological Association (AUA) Annual Meeting in New Orleans. [read more]
LOBSTER Clinical Trial to Advance Cxbladder Monitor as a Standard of Care
Pacific Edge today announces it is advancing its clinical evidence generation program with LOBSTER – a clinical study focused on demonstrating the clinical utility of Cxbladder Monitor for surveillance of recurrent urothelial cancer. [read more]
Pacific Edge Full Year Result to be Announced 26 May 2022
Pacific Edge advises that its full year results for the 12 months to 31 March 2022 (FY22) will be released on Thursday 26 May 2022, prior to 10am. [read more]
Pacific Edge Opens Upgraded Dunedin Laboratory
Pacific Edge is pleased to announce the opening of its upgraded clinical laboratory at the University of Otago’s Centre for Innovation in Dunedin. [read more]
Pacific Edge Investor Newsletter - March 2022
Pacific Edge is pleased to present the latest edition of its regular Investor Newsletter. [read more]
Pacific Edge Appoints Tony Barclay to Its Board
Pacific Edge is pleased to confirm the appointment of Tony Barclay to its Board as an Independent Non-Executive Director. Mr Barclay, who takes up the role on 21 March, is a highly experienced healthcare industry leader with a deep experience of taking innovative NZ technology to international markets, including the US. [read more]
Dr Peter Meintjes Commences As Pacific Edge Chief Executive Officer
Pacific Edge is pleased to announce that Dr Peter Meintjes commenced as Chief Executive Officer of the company on 17 January. Dr Meintjes replaces Executive Director and Chief Executive David Darling, who announced his retirement in April 2021. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.